Profile data is unavailable for this security.
About the company
Hypera SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company operates in several markets with a variety of pharmaceutical products. The Company's products include: Mantecorp Farmasa, which is an under the umbrella brand; Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador, and Rinosoro, which focus on several medical specialties involving primary care which are present in main therapeutic classes; Mantecorp Skincare, which offer dermo cosmetics recommended by dermatologists and also operates in this segment with the brands Simple Organic, which offers organic, vegan, and cruelty-free products, and Bioage, which focuses on the professional aesthetic treatment market; and Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina, which are over-the-counter medications provided throughout Brazil.
- Revenue in BRL (TTM)6.97bn
- Net income in BRL825.30m
- Incorporated2001
- Employees9.00k
- LocationHypera SARua Nova Cidade, 404, Vila OlimpiaSAO PAULO 04.547-070BrazilBRA
- Phone+55 1 136274206
- Fax+55 1 136274371
- Websitehttps://www.hypera.com.br/
More ▼
Mergers & acquisitions
| Acquired company | HYPE3:SAO since announced | Transaction value |
|---|---|---|
| Simple Organic Beauty Ltda | 5.92% | -- |
Data delayed at least 15 minutes, as of Mar 06 2026 21:07 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kalbe Farma Tbk PT | 10.66bn | 1.08bn | 14.89bn | 12.78k | 13.38 | 2.02 | 11.00 | 1.40 | 76.62 | 76.62 | 754.10 | 507.01 | 1.17 | 3.08 | 6.47 | 2,664,288,000.00 | 12.05 | 12.17 | 15.24 | 15.15 | 39.50 | 40.06 | 10.31 | 10.97 | 2.36 | -- | 0.0206 | 52.79 | 7.16 | 7.59 | 17.13 | 5.27 | -8.81 | 12.47 |
| Hisamitsu Pharmaceutical Co Inc | 5.29bn | 664.32m | 15.09bn | 2.80k | 21.80 | 1.57 | 16.49 | 2.85 | 276.99 | 276.99 | 2,208.13 | 3,837.32 | 0.4704 | 2.64 | 3.42 | 56,901,390.00 | 6.04 | 4.34 | 7.25 | 4.99 | 59.05 | 57.83 | 12.84 | 10.32 | 3.28 | -- | 0.0086 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Twist Bioscience Corp | 2.05bn | -401.64m | 15.09bn | 979.00 | -- | 6.31 | -- | 7.35 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Emcure Pharmaceuticals Ltd | 5.05bn | 496.26m | 15.31bn | 6.73k | 30.84 | -- | 20.64 | 3.03 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Hypera SA | 6.97bn | 825.30m | 15.43bn | 9.00k | 17.17 | 1.15 | 13.78 | 2.21 | 1.28 | 1.28 | 10.85 | 19.16 | 0.2733 | 1.49 | 3.04 | -- | 3.22 | 7.37 | 3.98 | 8.92 | 56.70 | 62.47 | 11.77 | 23.17 | 0.8382 | -- | 0.4327 | 49.00 | -5.97 | 17.70 | -18.53 | 2.47 | 16.39 | 1.77 |
| Catalyst Pharmaceuticals Inc | 3.09bn | 1.12bn | 15.53bn | 182.00 | 14.39 | 3.11 | 11.74 | 5.03 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 11.56bn | 1.04bn | 15.57bn | 14.35k | 15.09 | 1.38 | -- | 1.35 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Arcutis Biotherapeutics Inc | 1.97bn | -84.65m | 15.61bn | 354.00 | -- | 15.62 | -- | 7.92 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Almirall SA | 6.75bn | 281.23m | 15.68bn | 2.11k | 55.52 | 1.73 | 34.69 | 2.32 | 0.2158 | 0.2158 | 5.15 | 6.92 | 0.4682 | 1.35 | 8.44 | 525,656.60 | 1.95 | -0.1648 | 2.29 | -0.1933 | 78.66 | 78.17 | 4.17 | -0.4008 | 1.53 | -- | 0.1874 | -- | 12.41 | 6.54 | 354.85 | -9.08 | 12.40 | -- |
| Gland Pharma Ltd | 3.49bn | 483.29m | 15.69bn | 4.35k | 32.46 | -- | 21.86 | 4.50 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| PegBio Co Ltd | -67.04bn | -67.04bn | 15.76bn | 58.00 | -- | 80.10 | -- | -- | -- | -- | -- | 0.7503 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.07 | -- | 0.2439 | -- | -- | -- | -1.49 | -- | -- | -- |
| Tasly Pharmaceutical Group Co Ltd | 6.35bn | 834.68m | 16.15bn | 10.96k | 19.35 | 1.73 | -- | 2.55 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
Data as of Mar 06 2026. Currency figures normalised to Hypera SA's reporting currency: Brazilian Real BRL
36.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tivio Capital Distribuidora De Titulos E Valores Mobiliariosas of 28 Aug 2025 | 69.81m | 11.02% |
| Perenne Investimentos Ltda.as of 28 Aug 2025 | 38.13m | 6.02% |
| Fidelity Management & Research Co. LLCas of 28 Aug 2025 | 31.79m | 5.02% |
| Mondrian Investment Partners Ltd.as of 06 May 2025 | 31.52m | 4.98% |
| Union Bancaire Priv�e, UBP SA (UK)as of 31 Oct 2025 | 14.98m | 2.37% |
| Plural Investimentos Gest�o de Recursos Ltda.as of 31 Oct 2025 | 13.59m | 2.15% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 11.82m | 1.87% |
| Templeton Asset Management Ltd.as of 31 Jan 2026 | 7.89m | 1.25% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 4.87m | 0.77% |
| BlackRock Brasil Gestora de Investimentos Ltda.as of 05 Feb 2026 | 4.02m | 0.64% |
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
